Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) has been assigned a $26.00 price objective by analysts at Piper Jaffray Companies in a note issued to investors on Thursday. The firm currently has a “buy” rating on the biopharmaceutical company’s stock. Piper Jaffray Companies’ price objective points to a potential upside of 62.50% from the company’s current price.

VNDA has been the subject of several other research reports. Zacks Investment Research upgraded shares of Vanda Pharmaceuticals from a “sell” rating to a “strong-buy” rating and set a $18.00 target price for the company in a research report on Tuesday, August 8th. BidaskClub cut shares of Vanda Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Friday, August 11th. HC Wainwright set a $18.00 target price on shares of Vanda Pharmaceuticals and gave the company a “buy” rating in a research report on Thursday, August 3rd. Oppenheimer Holdings, Inc. set a $21.00 target price on shares of Vanda Pharmaceuticals and gave the company a “buy” rating in a research report on Thursday, August 3rd. Finally, Jefferies Group LLC reiterated a “buy” rating and set a $21.00 target price on shares of Vanda Pharmaceuticals in a research report on Tuesday, August 29th. Two analysts have rated the stock with a hold rating and six have given a buy rating to the stock. The company has an average rating of “Buy” and a consensus target price of $21.29.

Shares of Vanda Pharmaceuticals (NASDAQ:VNDA) remained flat at $16.00 during trading on Thursday. The company’s stock had a trading volume of 304,408 shares. The stock’s market cap is $717.73 million. The stock’s 50-day moving average price is $17.38 and its 200 day moving average price is $15.71. Vanda Pharmaceuticals has a 1-year low of $12.70 and a 1-year high of $18.99.

Vanda Pharmaceuticals (NASDAQ:VNDA) last posted its quarterly earnings data on Wednesday, August 2nd. The biopharmaceutical company reported ($0.03) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.21) by $0.18. Vanda Pharmaceuticals had a negative return on equity of 7.85% and a negative net margin of 6.54%. The firm had revenue of $42.06 million for the quarter, compared to the consensus estimate of $40.31 million. During the same quarter in the prior year, the business earned $0.01 EPS. The business’s revenue for the quarter was up 16.7% compared to the same quarter last year. On average, equities analysts anticipate that Vanda Pharmaceuticals will post ($0.43) earnings per share for the current year.

COPYRIGHT VIOLATION WARNING: “Piper Jaffray Companies Analysts Give Vanda Pharmaceuticals Inc. (VNDA) a $26.00 Price Target” was posted by American Banking News and is the property of of American Banking News. If you are reading this news story on another website, it was copied illegally and republished in violation of U.S. and international trademark & copyright legislation. The legal version of this news story can be read at https://www.americanbankingnews.com/2017/10/21/piper-jaffray-companies-analysts-give-vanda-pharmaceuticals-inc-vnda-a-26-00-price-target.html.

Hedge funds have recently added to or reduced their stakes in the business. Legal & General Group Plc increased its holdings in Vanda Pharmaceuticals by 37.4% during the 2nd quarter. Legal & General Group Plc now owns 11,105 shares of the biopharmaceutical company’s stock worth $181,000 after purchasing an additional 3,022 shares in the last quarter. Kopp Investment Advisors LLC bought a new position in Vanda Pharmaceuticals during the 2nd quarter worth about $196,000. American International Group Inc. increased its holdings in Vanda Pharmaceuticals by 7.1% during the 1st quarter. American International Group Inc. now owns 22,563 shares of the biopharmaceutical company’s stock worth $316,000 after purchasing an additional 1,491 shares in the last quarter. Voya Investment Management LLC increased its holdings in Vanda Pharmaceuticals by 29.7% during the 2nd quarter. Voya Investment Management LLC now owns 20,118 shares of the biopharmaceutical company’s stock worth $328,000 after purchasing an additional 4,605 shares in the last quarter. Finally, Dynamic Technology Lab Private Ltd increased its holdings in Vanda Pharmaceuticals by 46.3% during the 2nd quarter. Dynamic Technology Lab Private Ltd now owns 20,510 shares of the biopharmaceutical company’s stock worth $335,000 after purchasing an additional 6,487 shares in the last quarter. Hedge funds and other institutional investors own 86.49% of the company’s stock.

Vanda Pharmaceuticals Company Profile

Vanda Pharmaceuticals Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of therapies to address unmet medical needs. Its product portfolio includes HETLIOZ (tasimelteon), Fanapt (iloperidone), Tradipitant (VLY-686), Trichostatin A and AQW051. It offers HETLIOZ for the treatment of Non-24-Hour Sleep-Wake Disorder (Non-24).

Analyst Recommendations for Vanda Pharmaceuticals (NASDAQ:VNDA)

Receive News & Ratings for Vanda Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vanda Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.